EA200500242A1 - Пиперидин-2,5-дионовые памоатные соли и их использование для лечения связанных со стрессом аффективных расстройств - Google Patents
Пиперидин-2,5-дионовые памоатные соли и их использование для лечения связанных со стрессом аффективных расстройствInfo
- Publication number
- EA200500242A1 EA200500242A1 EA200500242A EA200500242A EA200500242A1 EA 200500242 A1 EA200500242 A1 EA 200500242A1 EA 200500242 A EA200500242 A EA 200500242A EA 200500242 A EA200500242 A EA 200500242A EA 200500242 A1 EA200500242 A1 EA 200500242A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- salts
- treatment
- dimethylpiperidine
- dione
- affective disorders
- Prior art date
Links
- 208000019022 Mood disease Diseases 0.000 title abstract 2
- -1 PIPERIDIN-2,5-DIONAL Chemical compound 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- YOGIZNRHMDDKAA-UHFFFAOYSA-N 3-(3,5-dimethoxyphenyl)-3-[3-(dimethylamino)propyl]-4,4-dimethylpiperidine-2,6-dione Chemical compound COC1=CC(OC)=CC(C2(CCCN(C)C)C(CC(=O)NC2=O)(C)C)=C1 YOGIZNRHMDDKAA-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- UJFNSGBGJMRZKS-UHFFFAOYSA-N agn-2979 Chemical compound COC1=CC=CC(C2(CCCN(C)C)C(CC(=O)NC2=O)(C)C)=C1 UJFNSGBGJMRZKS-UHFFFAOYSA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 150000003840 hydrochlorides Chemical class 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Новые памоатные соли некоторых 3-фенил-3-диметиламиноалкил-4,4-диметилпиперидин-2,6-дионов (1) и их фармакологически приемлемые сольваты не вызывают потери в массе и изменений в гепатоцитах у крыс, которые были характерны для минимально эффективных уровней разрешенных клинических доз соответствующих гидрохлоридов при лечении или профилактике связанных со стрессом аффективных расстройств, таких как тревога, депрессия, мигрень или апноэ во сне. Предпочтительными памоатными солями являются 3-(3,5-диметоксифенил)-3-(3-диметиламинопропил)-4,4-диметилпиперидин-2,6-диона памоат и, в особенности, 3-(3-метоксифенил)-3-(3-диметиламинопропил)-4,4-диметилпиперидин-2,6-диона памоат.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0219639.2A GB0219639D0 (en) | 2002-08-22 | 2002-08-22 | Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders |
PCT/IB2003/003698 WO2004017970A1 (en) | 2002-08-22 | 2003-08-18 | Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200500242A1 true EA200500242A1 (ru) | 2005-08-25 |
EA007900B1 EA007900B1 (ru) | 2007-02-27 |
Family
ID=9942831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500242A EA007900B1 (ru) | 2002-08-22 | 2003-08-18 | Пиперидин-2,6-дионовые памоатные соли и их использование для лечения связанных со стрессом аффективных расстройств |
Country Status (23)
Country | Link |
---|---|
US (2) | US7514454B2 (ru) |
EP (1) | EP1539160B1 (ru) |
JP (1) | JP2005538146A (ru) |
KR (1) | KR20050038014A (ru) |
CN (1) | CN1678316A (ru) |
AT (1) | ATE330605T1 (ru) |
BR (1) | BR0313674A (ru) |
CA (1) | CA2495377A1 (ru) |
CY (1) | CY1105541T1 (ru) |
DE (1) | DE60306396T2 (ru) |
DK (1) | DK1539160T3 (ru) |
EA (1) | EA007900B1 (ru) |
ES (1) | ES2268474T3 (ru) |
GB (1) | GB0219639D0 (ru) |
GE (1) | GEP20074051B (ru) |
IL (1) | IL166941A (ru) |
MX (1) | MXPA05001919A (ru) |
NO (1) | NO20051471L (ru) |
NZ (1) | NZ538341A (ru) |
PL (1) | PL373416A1 (ru) |
PT (1) | PT1539160E (ru) |
UA (1) | UA80144C2 (ru) |
WO (1) | WO2004017970A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6987111B2 (en) * | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
GB0518763D0 (en) * | 2005-09-14 | 2005-10-19 | Prestwick Pharmaceuticals Inc | Treatment of hypertension |
BRPI0702900A2 (pt) * | 2006-06-28 | 2011-03-15 | Teva Pharma | formas cristalinas da atorvastatina |
WO2013150052A1 (en) | 2012-04-04 | 2013-10-10 | Intervet International B.V. | Soft chewable pharmaceutical products |
CN105727117A (zh) * | 2016-02-03 | 2016-07-06 | 瓮杰林 | 一种治疗前列腺增生的药物及其制备方法 |
CN106831594B (zh) * | 2017-01-18 | 2018-02-02 | 力赛生物医药科技(厦门)有限公司 | 可乐定双羟萘酸盐及其制备方法 |
CN115702894A (zh) * | 2021-08-11 | 2023-02-17 | 朱信红 | 一种用于止吐的缓释组合物及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1455687A (en) * | 1972-12-28 | 1976-11-17 | Aspro Nicholas Ltd | Pharmacologically active 3-phenyl-3-aminoalkyl-2,6-dioxo-hydro genated pyridines |
US4461771A (en) * | 1983-03-01 | 1984-07-24 | Gittos Maurice W | Treatment of migraine with dioxopiperidine derivatives |
DE3686622T2 (de) * | 1985-09-11 | 1993-04-01 | British Tech Group | Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen. |
GB2196251B (en) | 1986-09-08 | 1990-07-04 | Nat Res Dev | Anxiolytic compositions containing dioxopiperidine derivatives |
GB8716338D0 (en) | 1987-07-10 | 1987-08-19 | Nat Res Dev | Anti-anxiogenic compositions |
GB2379216A (en) * | 2001-08-28 | 2003-03-05 | Maurice Ward Gittos | Piperidin-2,6-dione salts useful for the treatment of stress-related affective disorders |
-
2002
- 2002-08-22 GB GBGB0219639.2A patent/GB0219639D0/en not_active Ceased
-
2003
- 2003-08-18 AT AT03792588T patent/ATE330605T1/de active
- 2003-08-18 UA UAA200501443A patent/UA80144C2/ru unknown
- 2003-08-18 NZ NZ538341A patent/NZ538341A/en not_active IP Right Cessation
- 2003-08-18 DE DE60306396T patent/DE60306396T2/de not_active Expired - Lifetime
- 2003-08-18 WO PCT/IB2003/003698 patent/WO2004017970A1/en active IP Right Grant
- 2003-08-18 PL PL03373416A patent/PL373416A1/xx not_active Application Discontinuation
- 2003-08-18 KR KR1020057002687A patent/KR20050038014A/ko not_active Application Discontinuation
- 2003-08-18 EA EA200500242A patent/EA007900B1/ru not_active IP Right Cessation
- 2003-08-18 CN CNA038199149A patent/CN1678316A/zh active Pending
- 2003-08-18 EP EP03792588A patent/EP1539160B1/en not_active Expired - Lifetime
- 2003-08-18 CA CA002495377A patent/CA2495377A1/en not_active Abandoned
- 2003-08-18 JP JP2004530467A patent/JP2005538146A/ja active Pending
- 2003-08-18 US US10/524,693 patent/US7514454B2/en not_active Expired - Fee Related
- 2003-08-18 ES ES03792588T patent/ES2268474T3/es not_active Expired - Lifetime
- 2003-08-18 MX MXPA05001919A patent/MXPA05001919A/es active IP Right Grant
- 2003-08-18 BR BR0313674-4A patent/BR0313674A/pt not_active Application Discontinuation
- 2003-08-18 DK DK03792588T patent/DK1539160T3/da active
- 2003-08-18 GE GEAP8650A patent/GEP20074051B/en unknown
- 2003-08-18 PT PT03792588T patent/PT1539160E/pt unknown
-
2005
- 2005-02-16 IL IL166941A patent/IL166941A/en not_active IP Right Cessation
- 2005-03-21 NO NO20051471A patent/NO20051471L/no not_active Application Discontinuation
-
2006
- 2006-09-15 CY CY20061101323T patent/CY1105541T1/el unknown
-
2009
- 2009-03-18 US US12/382,511 patent/US20090182012A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL166941A (en) | 2010-04-15 |
MXPA05001919A (es) | 2005-06-03 |
JP2005538146A (ja) | 2005-12-15 |
EP1539160B1 (en) | 2006-06-21 |
DE60306396T2 (de) | 2007-05-03 |
NZ538341A (en) | 2006-09-29 |
PL373416A1 (en) | 2005-08-22 |
PT1539160E (pt) | 2006-10-31 |
EA007900B1 (ru) | 2007-02-27 |
EP1539160A1 (en) | 2005-06-15 |
GEP20074051B (en) | 2007-02-26 |
DK1539160T3 (da) | 2006-10-09 |
US7514454B2 (en) | 2009-04-07 |
US20090182012A1 (en) | 2009-07-16 |
NO20051471L (no) | 2005-05-23 |
WO2004017970A1 (en) | 2004-03-04 |
ATE330605T1 (de) | 2006-07-15 |
US20060025443A1 (en) | 2006-02-02 |
CN1678316A (zh) | 2005-10-05 |
KR20050038014A (ko) | 2005-04-25 |
ES2268474T3 (es) | 2007-03-16 |
UA80144C2 (ru) | 2007-08-27 |
DE60306396D1 (de) | 2006-08-03 |
AU2003255947A1 (en) | 2004-03-11 |
GB0219639D0 (en) | 2002-10-02 |
CY1105541T1 (el) | 2010-07-28 |
CA2495377A1 (en) | 2004-03-04 |
BR0313674A (pt) | 2005-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
ATE530530T1 (de) | Diaminopyrimidincarbonsäureamidderivat | |
NO2014030I1 (no) | (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine. | |
ATE536353T1 (de) | 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren | |
IL191027A0 (en) | Treatment method | |
YU29102A (sh) | Heteroalkilamino-supstituisani biciklični azotni heterocikli kao inhibitori p38 protein kinaze | |
DE60234453D1 (de) | Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren | |
EA200500146A1 (ru) | Моноэтансульфонат 3-z-[1-4-(n-((4-метилпиперазин-1-ил)метилкарбонил)-n-метиламино)анилино)-1-фенилметилен]-6-метоксикарбонил-2-индолинона и его применение в составе фармацевтической композиции | |
DK1804804T3 (da) | 3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser | |
PL1706113T3 (pl) | Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu | |
ATE402149T1 (de) | Heterozyklische substituierte amide, deren herstellung und anwendung | |
EA200300527A1 (ru) | Новые способы лечения синдрома "усталых ног" | |
PT1240165E (pt) | Inibidores n-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]carboxamida de quinases dependentes da ciclina | |
NO20060020L (no) | 3-fluorpiperidiner som NMDA/NR2B-antagonister | |
NO20054744L (no) | Behandling av Alzheimers sykdom | |
DE60314013D1 (de) | 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten | |
ATE413388T1 (de) | Muskarin antagonisten | |
IS2473B (is) | Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess | |
EA200500242A1 (ru) | Пиперидин-2,5-дионовые памоатные соли и их использование для лечения связанных со стрессом аффективных расстройств | |
CY1105979T1 (el) | Νεα οξινα θειικα αλατα πιπepιδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |